Boswellia and Blood Pressure: What’s the Connection?

No human clinical trial has directly demonstrated that Boswellia supplements lower blood pressure, and anyone hoping for a straightforward “take this dose, expect this drop” answer will be disappointed. What does exist is a web of indirect evidence: a review confirming that Boswellia species show beneficial effects on metabolic syndrome and its related disorders including hypertension, plus animal and cell studies pointing to anti-inflammatory, lipid-lowering, and possibly vascular mechanisms that are all relevant to how blood pressure is regulated. The gap between those promising signals and a proven effect in living, breathing people with high blood pressure is real, and worth understanding before you spend money on frankincense extract capsules.

What the Research Literature Actually Says

The most comprehensive look at Boswellia and cardiovascular-metabolic conditions is a 2020 review published in the Iranian Journal of Basic Medical Sciences. It concluded that Boswellia species have beneficial effects in controlling metabolic syndrome and related disorders such as hyperglycemia, dyslipidemia, hypertension, obesity, and diabetes complications. The review also noted that Boswellia has antithrombotic and anticoagulant properties that help regulate blood pressure.¹ That sounds encouraging, but it is important to recognize what kind of evidence sits behind that statement. The review draws on a mix of animal experiments, cell-culture work, and human trials on related metabolic markers like blood sugar and cholesterol. It does not point to a single randomized controlled trial in which researchers gave Boswellia to people with hypertension, measured their blood pressure over time, and compared it to a placebo group. The claim about blood pressure regulation is an inference from the broader metabolic evidence, not a direct clinical finding.

This distinction matters because blood pressure is influenced by dozens of factors simultaneously, and a supplement that improves some of those factors in a lab dish or a rodent does not necessarily produce a measurable change in a person’s reading at the doctor’s office. The evidence for Boswellia and blood pressure is best described as biologically plausible but clinically unproven.

Mechanisms That Could Plausibly Influence Blood Pressure

Researchers have identified several pathways through which boswellic acids, the active compounds in Boswellia resin, might affect blood pressure. None of these has been confirmed in a human blood-pressure trial, but understanding them helps explain why scientists keep circling back to Boswellia in cardiovascular research.

Dampening Chronic Inflammation

Chronic low-grade inflammation damages blood vessel walls, promotes stiffness, and contributes to the development of high blood pressure over time. The best-studied boswellic acid, acetyl-11-keto-β-boswellic acid (AKBA), has shown strong anti-inflammatory activity in laboratory settings. In one cell study, pretreating heart muscle cells with AKBA before exposing them to a bacterial toxin significantly reduced levels of inflammatory messengers including IL-6, TNF-α, and nitric oxide metabolites, while also preserving cell viability.² In a mouse model of atherosclerosis, AKBA reduced plaque formation and lowered markers of blood vessel inflammation, delivering anti-inflammatory and anti-atherogenic effects.³ Less plaque and less arterial inflammation are both good news for blood pressure in theory, because stiffer, narrower arteries require higher pressure to push blood through.

Improving Lipid Profiles

High cholesterol and high triglycerides are not the same thing as high blood pressure, but they travel in the same circles. When LDL cholesterol builds up in artery walls, it triggers the inflammatory cascade that eventually stiffens vessels and raises pressure. In a human trial of type 2 diabetic patients, six weeks of Boswellia serrata supplementation significantly raised HDL (“good”) cholesterol and lowered total cholesterol, LDL, and liver enzymes compared to a control group.⁴ An animal study in obese rats found a similar pattern: Boswellia extract reduced total cholesterol, triglycerides, LDL, blood sugar, and inflammatory cytokines while raising HDL and adiponectin, a hormone linked to healthy metabolism.⁵

The lipid story is not perfectly tidy, though. The mouse atherosclerosis study mentioned above found that while AKBA reduced plaque and inflammation, it did not change plasma triglycerides, total cholesterol, or anti-oxidized LDL antibodies.³ So AKBA alone may not account for the lipid improvements seen with whole Boswellia extract. The resin contains dozens of active compounds, and the polyphenol-rich fraction used in the obese-rat study is not the same as a purified AKBA preparation. Whether the lipid benefits translate into blood pressure changes in humans remains an open question.

Possible Interaction with the Angiotensin System

Many of the most commonly prescribed blood pressure medications work by blocking angiotensin-converting enzyme (ACE) or the receptor for angiotensin II. At least one computational (in silico) study has modeled how phytocompounds from several plants, including Boswellia serrata, interact with ACE as a target protein.⁶ Computer modeling can suggest that a molecule fits into a protein’s active site, but that is a very early step. It says nothing about whether the compound reaches that site in meaningful concentrations inside the body, or whether the binding is strong enough to produce a real effect. This is worth mentioning because supplement marketers sometimes describe Boswellia as a “natural ACE inhibitor,” which dramatically overstates what the science actually supports.

The Stress and Anxiety Angle

Stress and anxiety raise blood pressure acutely and, when chronic, contribute to sustained hypertension. Boswellia resin contains a compound called incensole acetate, which is distinct from the boswellic acids that get most of the research attention. A study published in The FASEB Journal found that incensole acetate activates TRPV3 channels in the brain and produces anxiety-reducing and antidepressant-like behavioral effects in mice. Mice lacking the TRPV3 receptor did not show these effects, confirming that the channel is the mechanism.⁷ This finding is part of the reason frankincense burning has been associated with calming effects across many cultures for thousands of years.

Could reducing anxiety via incensole acetate lower blood pressure? In principle, yes, since a calmer nervous system produces less adrenaline and less vascular constriction. But this has not been tested as a blood pressure intervention. The TRPV3 study used mice, and the compound was delivered in a way that ensured brain exposure, which is a very different scenario from swallowing a supplement capsule and hoping enough reaches your brain. Still, for people whose blood pressure spikes are partly stress-driven, the anxiolytic potential of frankincense compounds is an intriguing thread in the larger tapestry.

A Long History of Traditional Use

Boswellia resin has been burned and consumed medicinally for millennia across the Middle East, India, China, and East Africa. Traditional applications include digestive ailments, skin infections, pain relief, and cardiovascular and neurological problems. China, the world’s largest market for frankincense, documents its efficacy in promoting blood circulation, relieving pain, reducing swelling, and promoting tissue regeneration in the Pharmacopoeia of the People’s Republic of China.⁸ The mention of “promoting blood circulation” is interesting because in traditional Chinese medicine, poor circulation and blood stagnation are considered root causes of many diseases, including conditions that overlap with what modern medicine calls hypertension.

Traditional use is not clinical proof, but it does tell you something: millions of people over centuries noticed effects after consuming or inhaling Boswellia resin, and cardiovascular effects were among them. The challenge for modern science is isolating which compounds are responsible and whether the effects are large enough to matter clinically.

The Bioavailability Problem

One reason the gap between laboratory promise and clinical results is so wide for Boswellia is that the active compounds are poorly absorbed by the human body. Standard boswellic acid extracts have low systemic absorption after oral dosing, especially the two most pharmacologically active forms, KBA and AKBA. A pharmacokinetic study comparing a standard Boswellia serrata extract with a soy lecithin formulation (marketed as Casperome) found dramatically different absorption profiles. The lecithin-based formulation delivered plasma levels up to seven times higher for KBA and three times higher for β-boswellic acid. Brain concentrations of KBA and AKBA were about 35 times higher with the lecithin formulation, and levels in poorly vascularized tissues like the eye were up to 17 times higher.⁹

For anyone considering Boswellia supplements for any purpose, this is practical information. A cheap, generic frankincense extract may deliver very little of the active compound into your bloodstream. The formulation matters enormously, and two products with identical milligram amounts of boswellic acids on the label can produce vastly different blood levels. If future clinical trials do eventually test Boswellia for blood pressure, the choice of formulation will almost certainly influence the results. This is one reason why extrapolating from positive animal studies to human expectations is risky: animal studies often use high doses or delivery methods that bypass the absorption problem entirely.

Drug Interactions with Blood Pressure Medications

If you are already taking medication for high blood pressure, Boswellia’s interaction profile deserves attention. Extracts from multiple Boswellia species, including B. serrata, B. carteri, B. sacra, and B. frereana, have been identified as potent, non-selective inhibitors of several major cytochrome P450 enzymes, specifically CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4.¹⁰ These enzymes are responsible for breaking down a huge proportion of prescription drugs, including many commonly used blood pressure medications.

Here is why that matters in practical terms. When you take a medication for blood pressure, your liver uses CYP enzymes to metabolize it at a predictable rate. Your doctor calibrates the dose assuming that metabolism is happening normally. If Boswellia inhibits those enzymes, the drug stays in your system longer and at higher concentrations than expected. The result could be an exaggerated blood pressure drop, dizziness, or other side effects that would not occur at the prescribed dose alone. Calcium channel blockers, some beta-blockers, and several ARBs (angiotensin receptor blockers) are metabolized by CYP3A4 or CYP2C9, two of the enzymes that Boswellia inhibits. Losartan, for instance, relies on CYP2C9 and CYP3A4 for conversion to its active metabolite, and interference with those pathways could alter its effectiveness in either direction.

This is not a reason to panic if you have taken a Boswellia supplement alongside your medication once or twice, but it is a reason to talk to a pharmacist or doctor before making it a daily habit. The inhibition was described as “potent” and “non-selective,” meaning it was not weak and it hit multiple enzyme pathways simultaneously. That combination raises the risk of clinically meaningful interactions.

Why Direct Blood Pressure Trials Have Not Happened

Given all these suggestive findings, it is fair to wonder why no one has simply run a trial giving Boswellia to people with hypertension and measuring the result. Several factors explain the gap. Hypertension trials are expensive and lengthy because meaningful blood pressure changes need to be tracked over months to years, with large enough groups to separate a real effect from normal day-to-day variation. Funding for such trials typically comes from pharmaceutical companies with a patentable drug at stake, and you cannot patent a tree resin that has been used for thousands of years. Academic funding agencies tend to prioritize conditions where Boswellia’s evidence is stronger, like osteoarthritis and inflammatory bowel disease, rather than a speculative cardiovascular application.

The bioavailability issue compounds the problem. Designing a trial requires choosing a specific formulation and dose, and as the lecithin study showed, different formulations produce wildly different blood levels. Researchers would need to first establish which formulation reliably delivers enough active compound to matter, then run the blood pressure trial. That is two expensive studies, not one. Add the fact that the existing mechanistic evidence points to several different pathways (inflammation, lipids, possibly ACE, possibly stress reduction), and you have a research question that is hard to pin down with a single clean trial design.

What You Can and Cannot Reasonably Expect

If you are taking Boswellia for another condition, like joint pain or digestive inflammation, and you also happen to have elevated blood pressure, the existing evidence suggests you are unlikely to see a dramatic blood pressure drop from the supplement alone. The metabolic improvements seen in the human diabetic trial, particularly the lipid changes, are the kind of thing that might contribute to better cardiovascular health over years, not the kind of thing that shows up on your home blood pressure monitor next Tuesday. And those lipid results came from patients with type 2 diabetes, a population with specific metabolic dysfunction. Whether healthy people or people with garden-variety hypertension would see similar changes is unknown.

The anti-inflammatory effects are real in laboratory settings and animal models, and chronic inflammation genuinely does contribute to hypertension. But “reduces inflammation in a dish” and “lowers your blood pressure” are separated by an enormous distance in biology. Many compounds that look promising in early-stage research fail to produce meaningful effects in people. Boswellia might eventually join the short list of natural products with proven cardiovascular benefits, but right now, the evidence puts it firmly in the “interesting but unproven” category for blood pressure specifically.

How Boswellia Compares to Supplements with Stronger Blood Pressure Evidence

For context, several natural products have been tested in randomized controlled trials specifically measuring blood pressure as a primary outcome, and some have shown modest but real effects. Hibiscus tea, beetroot juice (via dietary nitrate), and certain forms of omega-3 fatty acids have accumulated enough trial data to support cautious claims about blood pressure reduction. Boswellia has not reached that level of evidence for this particular application. Its strongest human evidence is in inflammatory conditions and, to a lesser extent, metabolic markers in diabetic patients. That does not mean it is ineffective for blood pressure; it means no one has adequately tested the question yet.

People sometimes assume that because a supplement helps with inflammation, and inflammation contributes to high blood pressure, the supplement must lower blood pressure. That logic has a gap in the middle. Inflammation is one contributor among many, and reducing it does not guarantee a net blood pressure change large enough to detect, let alone large enough to matter clinically. The body has redundant systems for maintaining blood pressure, and addressing one contributing factor may not budge the overall reading if other factors (sodium intake, weight, genetics, kidney function, arterial stiffness from aging) are the dominant drivers in a given person.

Frankincense Smoke Versus Oral Supplements

The traditional use of Boswellia often involves burning the resin and inhaling the smoke, which is pharmacologically distinct from swallowing an extract capsule. The anxiolytic effects of incensole acetate, for example, were demonstrated through a route that delivered the compound to the brain. Burning frankincense volatilizes different compounds than those that survive stomach acid and liver metabolism after oral dosing. This means that the calming, potentially blood-pressure-relevant effects of burning frankincense may not be replicated by taking a pill, and vice versa. The two delivery methods expose you to overlapping but different chemical profiles.

For someone interested in the stress-reduction angle specifically, there is a certain irony: the most evidence-supported anxiolytic compound in Boswellia (incensole acetate) is not the same as the most studied anti-inflammatory compounds (the boswellic acids like AKBA). Most commercially available supplements are standardized for boswellic acid content, not incensole acetate. If your interest is calming effects, the traditional practice of burning frankincense resin may actually deliver more of the relevant compound than a standardized extract pill, though neither route has been tested in a blood pressure trial. The research world has largely treated Boswellia’s anti-inflammatory and psychoactive properties as separate stories, and no one has tried to put them together in the context of cardiovascular health.